|

IL-2 Clinical Trials

5 actively recruiting trials across 3 locations

▼ -1 trial since June 2026

Also known as: Aldesleukin, Cellular interleukin 2, interleukin-2

Pipeline

Phase 1: 3Phase 1/2: 2

Top Sponsors

  • Washington University School of Medicine1
  • TCRCure Biopharma Ltd.1
  • Masonic Cancer Center, University of Minnesota1
  • Imugene Limited1
  • Guangzhou FineImmune Biotechnology Co., LTD.1

Indications

  • Cancer5
  • Tumor Associated Lymph Node T Cell1
  • Acute Myeloid Leukemia, Pediatric1
  • Relapsed Adult AML1
  • Acute Myelogenous Leukemia1

Other2 trials

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors
Phase 1
Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Phase 1

Gilbert, Arizona1 trial

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Banner MD Anderson Cancer Center

Phase 1

Minneapolis, Minnesota1 trial

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Mark Juckett, MD

Phase 1/2

St Louis, Missouri1 trial

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Washington University School of Medicine

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.